Momenta announces new focus on AmAb biosimilar

Oct 1, 2018

Momenta announces an end to its strategic review, revealing a sole focus to advance a Humira® biosimilar. Momenta announced it will file a BLA with the FDA and is working to find a commercialisation partner for the product. 

Print Page Mail Article